[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369071-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369071-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pancreatic-cancer-in-the-era-of-precision-medicine-challenges-advances-and-the-future-of-therapeutic-strategies","Pancreatic cancer in the era of precision medicine - challenges, advances, and the future of therapeutic strategies","","Pancreatic cancer is among the most aggressive and fatal malignancies, with rising global incidence and major clinical consequences for patients and health systems. Progress is hindered by difficulties in early detection, limited therapeutic efficacy, and frequent late-stage diagnoses driven by the disease’s initial asymptomatic nature and lack of reliable early biomarkers. Tumor biological complexity, including genetic mutations and an immunosuppressive microenvironment, contributes to resistance and worsens treatment outcomes. Narrative synthesis covers challenges and recent advances in precision-based therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pancreatic-cancer-in-the-era-of-precision-medicine-challenges-advances-and-the-future-of-therapeutic-strategies/369071/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pancreatic-cancer-in-the-era-of-precision-medicine-challenges-advances-and-the-future-of-therapeutic-strategies/369071.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early diagnosis of pancreatic cancer so difficult?","Question",{"text":63,"@type":64},"Its early stages are often asymptomatic, and there are no reliable early biomarkers, leading to frequent late-stage diagnoses and reduced treatment success.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the tumor microenvironment affect treatment?",{"text":68,"@type":64},"A dense fibrotic stroma and immunosuppressive cellular composition can impede drug delivery and immune system activation, supporting resistance to conventional therapies.",{"name":70,"@type":61,"acceptedAnswer":71},"What emerging therapies are highlighted for the future?",{"text":72,"@type":64},"The review discusses combination chemotherapy and advanced radiotherapy to improve precision, along with immunotherapies such as mRNA-based vaccines and engineered cellular therapies, and targeted approaches linked to specific genetic alterations like KRAS mutations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369071,1791332172,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Silva and Rosa  \nJournal of the Egyptian National Cancer Institute (2025) 37:64  \n[https://doi.org/10.1186/s43046-025-00323-w](https://doi.org/10.1186/s43046-025-00323-w)  \nJournal of the Egyptian National Cancer Institute  \n REVIEW Open Access  \nPancreatic cancer in the era of precision  \nmedicine: challenges, advances, and the future of therapeutic strategies  \nHeslley Machado Silva1,2* and Reginaldo Cruz Alves Rosa3,4  \nAbstract  \nBackground Pancreatic cancer stands among the most aggressive and fatal malignancies, with a steadily increasing incidence worldwide. Its clinical significance lies not only in its high mortality rate but also in the challenges associated with its early detection, limited therapeutic efficacy, and substantial impact on healthcare systems. The asymptomatic nature of the disease in its initial stages, combined with the absence of reliable early biomarkers, contributes to frequent late-stage diagnoses, significantly compromising treatment success and patient survival. Furthermore, the biological complexity of pancreatic tumors – often marked by specific genetic mutations and a highly immunosuppressive tumor microenvironment – drives resistance to conventional therapies, exacerbating clinical management difficulties.  \nMain body This narrative review offers a comprehensive synthesis of the major therapeutic challenges and recent advances in pancreatic cancer management over the past fifteen years. The main challenges include delayed diagnosis, the presence of treatment-resistant tumor subtypes, and the considerable financial burden of care. Particular attention is given to the tumor microenvironment, which impedes drug delivery and immune system activation due to its dense fibrotic stroma and immunosuppressive cellular composition. The review also explores emerging therapeutic strategies, including combination chemotherapy regimens such as folinic acid, fluorouracil, irinotecan, and oxaliplatin, and advanced radiotherapy techniques that aim to enhance precision while minimizing tissue damage. Furthermore, novel immunotherapeutic approaches – including messenger RNA-based vaccines and engineered cellular therapies – show promising results in stimulating targeted immune responses, although they face substantial barriers due to the tumor’s immune evasion mechanisms. Targeted therapies focused on specific genetic alterations, especially those involving KRAS mutations, are also highlighted as potential breakthroughs. The review concludes by emphasizing the relevance of personalized medicine, with biomarker-driven strategies and three-dimensional tumor models offering more tailored and potentially effective interventions.  \nConclusion Despite meaningful progress in the development of innovative therapeutic modalities, pancreatic cancer continues to present profound medical and scientific challenges. Integrating personalized, interdiscipli  \nnary approaches and advancing early diagnostic tools remain essential steps toward improving clinical outcomesand extending survival in affected patients. This review underscores the urgent need for continued research to transform current insights into effective and accessible treatment strategies.  \nKeywords Pancreatic cancer, Immunotherapy, Late-stage diagnosis, Personalized medicine, Targeted therapies  \n*Correspondence: Heslley Machado Silva [heslley@uniformg.edu.br](heslley@uniformg.edu.br)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated","cbCaikq7xRabWyp6","https://ap.wps.com/l/cbCaikq7xRabWyp6","pdf",1606754,11,"English","# Abstract\n# Introduction\n# Global incidence and risk factors\n# Therapeutic challenges and advances\n## Tumor microenvironment and treatment resistance\n## Emerging strategies: chemotherapy and radiotherapy\n## Immunotherapeutic approaches and targeted therapies\n# Conclusion","[{\"question\":\"Why is early diagnosis of pancreatic cancer so difficult?\",\"answer\":\"Its early stages are often asymptomatic, and there are no reliable early biomarkers, leading to frequent late-stage diagnoses and reduced treatment success.\"},{\"question\":\"How does the tumor microenvironment affect treatment?\",\"answer\":\"A dense fibrotic stroma and immunosuppressive cellular composition can impede drug delivery and immune system activation, supporting resistance to conventional therapies.\"},{\"question\":\"What emerging therapies are highlighted for the future?\",\"answer\":\"The review discusses combination chemotherapy and advanced radiotherapy to improve precision, along with immunotherapies such as mRNA-based vaccines and engineered cellular therapies, and targeted approaches linked to specific genetic alterations like KRAS mutations.\"}]","Pancreatic cancer in the era of precision medicine - challenges, advances, and the future of therapeutic strategies | PDF",1790180519,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fda3317082d73248e1ac5611e53f72ab.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/008833d98506ebcabf36f196fc4585ef.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/753727c25528f0d1b541e0216f56fd4c.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/57a07e46fb5b8466cfdff540d9b2f8bc.webp",980,1301]